Cargando…

单中心22例获得性血友病的回顾性临床研究

OBJECTIVE: To investigate the feature of underlying disorders, clinical symptoms, diagnosis and treatment strategies of patients with acquired hemophilia(AH). METHODS: The clinical data and laboratory tests results of 22 patients with AH from March 2010 to June 2014 were retrospectively analyzed. RE...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342156/
https://www.ncbi.nlm.nih.gov/pubmed/25778884
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.02.005
_version_ 1783555388078030848
collection PubMed
description OBJECTIVE: To investigate the feature of underlying disorders, clinical symptoms, diagnosis and treatment strategies of patients with acquired hemophilia(AH). METHODS: The clinical data and laboratory tests results of 22 patients with AH from March 2010 to June 2014 were retrospectively analyzed. RESULTS: A total of 22 patients with AH were enrolled in our study, including 20 patients diagnosed as acquired hemophilia A (AHA) and 2 as acquired hemophilia B (AHB). Among the AHA patients, there were 10 males and 10 females with the median age of 37.5 (range, 2–95) years old. The median activity of FⅧ (FⅧ∶C) of the 20 AHA patients was 1.9% (0.5%–39.0%). Soft tissue hematoma (80.0%) and subcutaneous bleeding (75.0%) were the most common clinical symptoms. Two male children were diagnosed as AHB (age 1 and 3 years old, respectively) with mild bleeding symptoms, and the activities of FⅨ (FⅨ∶C) were 5.0% and 16.0%, respectively. In addition, an underlying disorder was found in 7 patients (31.8%). In laboratory testing, all patients had prolonged APTT, normal PT, decreased F Ⅷ∶C or F Ⅸ∶C, positive antibody screening test or antibody titer (2–32 BU), and negative for lupus anticoagulant and anticardiolipin antibody. Nineteen out of 20 patients were treated with blood products to stop acute bleeding episodes. Corticosteroid alone was applied to 7 patients, corticosteroid combined with other immunosuppressive agents to 11 patients, rituximab to 3 patients. Nineteen patients responded well to hemostatic treatment, except 1 patient who died of fatal bleeding. The FⅧ∶C of 8 patients increased to a normal level with the median time of 42.5 (21–145) days. After treatment, the activity of FⅨ∶C of the 2 AHB patients achieved 35% and 24% in 48 and 60 days, respectively. CONCLUSION: Acquired hemophilia is not an uncommon disease in clinical practices, which can occur in people of all ages. AH is a bleeding disorder with heterogeneous characteristics. Compared with adult, the clinical symptoms of children patients were mild, which lead to underdiagnosis.
format Online
Article
Text
id pubmed-7342156
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73421562020-07-16 单中心22例获得性血友病的回顾性临床研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the feature of underlying disorders, clinical symptoms, diagnosis and treatment strategies of patients with acquired hemophilia(AH). METHODS: The clinical data and laboratory tests results of 22 patients with AH from March 2010 to June 2014 were retrospectively analyzed. RESULTS: A total of 22 patients with AH were enrolled in our study, including 20 patients diagnosed as acquired hemophilia A (AHA) and 2 as acquired hemophilia B (AHB). Among the AHA patients, there were 10 males and 10 females with the median age of 37.5 (range, 2–95) years old. The median activity of FⅧ (FⅧ∶C) of the 20 AHA patients was 1.9% (0.5%–39.0%). Soft tissue hematoma (80.0%) and subcutaneous bleeding (75.0%) were the most common clinical symptoms. Two male children were diagnosed as AHB (age 1 and 3 years old, respectively) with mild bleeding symptoms, and the activities of FⅨ (FⅨ∶C) were 5.0% and 16.0%, respectively. In addition, an underlying disorder was found in 7 patients (31.8%). In laboratory testing, all patients had prolonged APTT, normal PT, decreased F Ⅷ∶C or F Ⅸ∶C, positive antibody screening test or antibody titer (2–32 BU), and negative for lupus anticoagulant and anticardiolipin antibody. Nineteen out of 20 patients were treated with blood products to stop acute bleeding episodes. Corticosteroid alone was applied to 7 patients, corticosteroid combined with other immunosuppressive agents to 11 patients, rituximab to 3 patients. Nineteen patients responded well to hemostatic treatment, except 1 patient who died of fatal bleeding. The FⅧ∶C of 8 patients increased to a normal level with the median time of 42.5 (21–145) days. After treatment, the activity of FⅨ∶C of the 2 AHB patients achieved 35% and 24% in 48 and 60 days, respectively. CONCLUSION: Acquired hemophilia is not an uncommon disease in clinical practices, which can occur in people of all ages. AH is a bleeding disorder with heterogeneous characteristics. Compared with adult, the clinical symptoms of children patients were mild, which lead to underdiagnosis. Editorial office of Chinese Journal of Hematology 2015-02 /pmc/articles/PMC7342156/ /pubmed/25778884 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.02.005 Text en 2015年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
单中心22例获得性血友病的回顾性临床研究
title 单中心22例获得性血友病的回顾性临床研究
title_full 单中心22例获得性血友病的回顾性临床研究
title_fullStr 单中心22例获得性血友病的回顾性临床研究
title_full_unstemmed 单中心22例获得性血友病的回顾性临床研究
title_short 单中心22例获得性血友病的回顾性临床研究
title_sort 单中心22例获得性血友病的回顾性临床研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342156/
https://www.ncbi.nlm.nih.gov/pubmed/25778884
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.02.005
work_keys_str_mv AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū
AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū
AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū
AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū
AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū
AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū
AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū
AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū
AT dānzhōngxīn22lìhuòdéxìngxuèyǒubìngdehuígùxìnglínchuángyánjiū